BMS submits marketing applications for entecavir to treat HBV in US and Europe
Bristol-Myers Squibb Company has announced the submission of a New Drug Application to the US Food and Drug Administration for entecavir, an investigational antiviral agent under development for the treatment of chronic Hepatitis B.
The company also submitted a marketing authorisation application for entecavir to the European Medicines Evaluation Agency.
Entecavir is an investigational oral antiviral discovered at Bristol-Myers Squibb that is designed to selectively inhibit the Hepatitis B virus, blocking all three steps in the replication process.
Source: BMS press release